Kraig Biocraft Laboratories In Stock Price, News & Analysis

Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its third and largest production cycle of spider silk for 2024. This expanded cycle, released in scheduled batches, aims to address the rainy season peak while driving towards 2024 production volume goals. The company has brought an additional production facility online to support increased silkworm rearing and silk production.

Kraig Labs expects to add more facilities over the next two months, supporting its goal of delivering the first metric ton of spider silk to global markets. Each production cycle further validates the company's spider silk production model and demonstrates its specialized silkworms' readiness for mass production. The company's CEO, Kim Thompson, described 2024 as an inflection point for spider silk commercialization.

Kraig Biocraft Laboratories (OTCQB: KBLB) has completed phase one of its spider silk production facility expansion on budget and on schedule. The expanded facility will support the company's third production wave starting this month, allowing for continued production during the rainy season. Key points include:

- New space for processing, drying, and storing fresh mulberry
- Ongoing construction of a larger silkworm egg hatchery
- Hatchery expected to address production needs for 12-18 months
- Part of systematic growth plan for commercial-scale spider silk production

CEO Kim Thompson emphasized these investments will help bring cost-effective and eco-responsible spider silk to global markets.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a new production agreement for its recombinant spider silk technology. This agreement aims to enhance the company's production capabilities by collaborating with existing silk manufacturers to adapt their facilities to produce Kraig Labs’ proprietary spider silk. The deal underscores the company's ongoing efforts to commercialize spider silk production, following the rollout of new production hybrids earlier this year. CEO Kim Thompson highlighted the company's commitment to expanding its production footprint and capacity, emphasizing the potential of commercial-scale spider silk. For more details, visit Kraig Labs' website.

Kraig Biocraft Laboratories (OTCQB: KBLB) has reached full capacity at its current production site, fulfilling its expansion goals for early 2024. The company is advancing with plans for additional production facilities. This expansion, initiated after observing strong growth in new spider silk hybrids, will occur in two phases. The first phase, addressing near-term capacity needs, is set for completion within weeks. The larger second phase, which will provide hatchery space for the next 12-18 months, will conclude by early fall. Permitting has been approved, and construction is underway. CEO Kim Thompson emphasized the company's commitment to achieving ambitious spider silk production targets in 2024. The expansion aligns with Kraig Labs' vision for cost-effective, commercial-scale spider silk production. The third wave of recombinant spider silk production will begin this month, focusing on scaling up output.

Kraig Biocraft Laboratories announces a significant increase in spider silk production with the next generation of BAM-1 hybrid eggs. Following the successful production of the first BAM-1 hybrid cocoons, the company scaled up its egg production, marking the largest batch in its history. These eggs are scheduled for rearing within the next 30 days, aiming to optimize spider silk output over the next 60 days, despite August's challenging weather conditions. CEO Kim Thompson noted that the first half of 2024 has been the most productive period for the company, meeting aggressive goals for BAM-1 hybrids and expanding production capabilities.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful completion of cocoon production for its first commercial run of BAM-1 spider silk hybrids. The production, launched 30 days ahead of schedule, achieved a 10x increase in volume compared to spring trials, generating over 325 pounds of cocoons. This marks the largest batch of recombinant spider silk ever produced. Kraig Labs aims to scale up production further to meet its metric-ton-level goal, leveraging the robustness of BAM-1 hybrids for large-scale manufacturing. CEO Kim Thompson emphasized the success and potential for rapid scale-up in 2024.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced a significant production update for its BAM-1 spider silk hybrid strain. The new batch, the largest in the company's history, is ten times the size of the spring trials and showcases record-breaking growth and robustness in silkworms.

The production batch is a major step forward in validating the rearing protocols and demonstrating the scalability of their spider silk production technology. CEO Kim Thompson emphasized that the mission of rapidly commercializing cost-effective and environmentally responsible spider silk production is progressing towards reality. The company plans to release cocooning and processing results over the coming weeks as it targets metric ton production levels.

Kraig Biocraft Laboratories (OTCQB: KBLB) announces the production of its BAM-1 recombinant spider silk hybrids, ahead of schedule due to successful production trials. This marks the company’s first true production-scale launch of these hybrids, representing over a 10x increase in production compared to spring trials. The BAM-1 hybrids, created by integrating Dragon Silk™ with robust silkworm strains, have shown excellent hatching yields, strong growth, and no signs of disease. This cycle aims to reach a production milestone of a metric ton of spider silk, with further updates promised in the coming weeks.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, first introduced in February 2024. The BAM-1 platform has proven to be the most resilient and efficient system for large-scale spider silk production. This technology has successfully integrated the desirable properties of spider silk into production-ready silkworm strains, resulting in the advanced Dragon SilkTM. CEO Kim Thompson emphasized the scalability and reliability of the BAM-1 hybrids in accelerating the market transition of spider silk technologies. Following successful spring production trials, the company is ahead of its 2024 production schedule and plans to expand production further in the coming weeks.